Related Experiment Video

Updated: Jun 16, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

[Outlook: Future therapy of renal cell carcinoma]

Lothar Bergmann1, Kurt Miller

  • 1Medizinische Klinik II, Hämatologie/Onkologie, J.W. Goethe-Universität, Frankfurt/M.

Onkologie
|February 19, 2010
PubMed

Insights

Targeted therapies have improved metastatic renal cell carcinoma (mRCC) treatment, offering better patient prognoses. Future research focuses on optimizing current options and exploring new combinations for earlier disease intervention.

Area of Science:

  • Oncology
  • Nephrology
  • Pharmacology

Background:

  • Metastatic renal cell carcinoma (mRCC) treatment has been revolutionized by targeted therapies.
  • Sunitinib is a current first-line standard, with other agents like Temsirolimus, Everolimus, Bevacizumab, and Sorafenib available.
  • These advancements have significantly improved the prognosis for mRCC patients.

Purpose of the Study:

  • To provide an overview of ongoing research in renal cell carcinoma (RCC) therapy.
  • To offer insight into the future therapeutic landscape for RCC.
  • To highlight key aspects of future RCC treatment development.

Main Methods:

  • Review of current targeted therapies for mRCC.
  • Analysis of ongoing clinical studies and research activities.
  • Discussion of future directions in RCC treatment optimization.

Main Results:

  • Targeted therapies have expanded treatment options for mRCC.
  • Improved patient prognosis is a direct result of these therapeutic advancements.
  • Ongoing research aims to further enhance treatment efficacy and application timing.

Conclusions:

  • The therapeutic arsenal for mRCC has grown, leading to better outcomes.
  • Future RCC therapy will likely involve optimizing existing targeted agents.
  • Research is exploring novel combinations, sequences, and applications (adjuvant/neoadjuvant) for targeted therapies in RCC.

More Related Videos

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Kidney Transplant III: Nursing Management01:16

Kidney Transplant III: Nursing Management

Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living donor...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...